A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
מצבים רפואיים
Advanced Solid Tumor · Metastatic Solid Tumor · Soft Tissue Sarcoma (STS) · Platinum-resistant Ovarian Cancer (PROC) · Hepatocellular Carcinoma (HCC) · Colorectal Cancer (CRC) · HER2 Negative Breast Cancer · Cutaneous Melanoma · Renal Cell Carcinoma (RCC)
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Mahesh Seetharam, MD)Mayo Clinic in Florida, Jacksonville, Florida, United States
Contact: Study coordinator (Yujie Zhao, MD, PhD)Mayo Clinic in Minnesota, Rochester, Minnesota, United States
Contact: Study coordinator (Jian Li Campian, MD, PhD)Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Viswatej Avutu, MD)Cleveland Clinic, Cleveland, Ohio, United States
Contact: Study coordinator (Wen Wee Ma, MBBS)Seoul National University Hospital, Seoul, Seoul, South Korea
Contact: Study coordinator (Seock-Ah Im, MD, PhD)St. Vincent's Hospital, Suwon, suwon, South Korea
Contact: Study coordinator (Byoung Yong Shim, MD, PhD)Yonsei University Health System, Severance Hospital, Seoul, South Korea
Contact: Study coordinator (Byoung Chul Cho, MD, PhD)Yonsei University Health System, Severance Hospital, Seoul, South Korea
Contact: Study coordinator (Jung-Yun Lee, MD, PhD)Asan Medical Center, Seoul, South Korea
Contact: Study coordinator (Jae-Lyun Lee, MD, PhD)Samsung Medical Center, Seoul, South Korea
Contact: Study coordinator (Seung Tae Kim, MD, PhD)
מובילי המחקר
Nari Yun, PhD
Study Director
GI Innovation, Inc.